EUCTR2004-002783-24-GBActive, not recruitingNot Applicable
Prednisolone versus Dexamethasone in Chronic inflammatory demyelinating polyradiculoneuropathy Trial; PREDICT-trial - PREDICT trial
Trial Snapshot
- Phase
- Not Applicable
- Status
- Active, not recruiting
- Sponsor
- AMC Medical research BV
- Enrollment
- 52
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional clinical trial of medicinal product
Eligibility Criteria
- Sex
- All
Inclusion Criteria
- •Eligible patients have to have signs and symptoms consistent with CIDP according to the diagnostic criteria as defined by a Dutch Consensus group in 1997. These criteria are derived from the much used and cited criteria of the ad hoc subcommittee of the American Academy of Neurology AIDS Task Force 1991 but contain a few practical modifications. Only definite or probable CIDP patients will be included.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
Exclusion Criteria
- •1. Abnormal erythrocyte sedimentation rate, hemoglobuline, white cell count, immuno-electrophoresis or immunofixation (with the exception of a IgG MGUS), TSH, Vitamin B1/B12, gamma-GT, or glucose
- •2. Pleocytosis in cerebrospinal fluid (CSF) of more than 90/3 (30/mm3)
- •3. Received treatment for CIDP before
- •4. Use of drugs which are known to cause neuropathy
- •5. Age under 18 years
- •6. Contraindication for corticosteroid treatment
- •7. Pregnancy or active wish to become pregnant
- •8. Diseases known to cause neuropathy or to reduce mobility
- •9. Diseases known to lead to severe handicap or death at short notice
- •10. Patients with a subacute inflammatory demyelinating polyneuropathy (SIDP); this is a subset of patients with spontaneous recovery within 3 months and a monophasic course
- •11. Pure motor CIDP: no sensory signs or symptoms and no abnormalities in sensory nerve conduction studies (SNAP, SNCV, SDLT)
- •12. Refusal to give informed consent or withdrawal of previously given permission
Investigators
Similar Trials
Completed
Not Applicable
Prednisolone versus dexamethasone in chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) trialChronic inflammatory demyelinating polyradiculoneuropathyNervous System DiseasesInflammatory polyneuropathyISRCTN07779236Academic Medical Centre (AMC) (The Netherlands)52
Recruiting
Phase 1
Comparison of Prednisolone and Dexamethasone on D28 mortality in patients on oxygen therapy with CoViD-19Care of severe forms of CoViD-19 from the transitional phase and the onset of the inflammatory phase with corticosteroidsMedDRA version: 23.0Level: LLTClassification code 10084270Term: SARS-CoV-2 acute respiratory diseaseSystem Organ Class: 10021881 - Infections and infestationsMedDRA version: 23.0Level: LLTClassification code 10084272Term: SARS-CoV-2 infectionSystem Organ Class: 10021881 - Infections and infestationsMedDRA version: 23.0Level: PTClassification code 10084268Term: COVID-19System Organ Class: 10021881 - Infections and infestationsMedDRA version: 21.1Level: LLTClassification code 10042839Term: Syndrome respiratory distress adultSystem Organ Class: 100000004855MedDRA version: 23.1Level: LLTClassification code 10084401Term: COVID-19 respiratory infectionSystem Organ Class: 10021881 - Infections and infestationsEUCTR2020-005883-78-FRHospital Center rené Dubos
Recruiting
Phase 4
A clinical trial to study the effects of two drugs,Methylprednisolone and Dexamethasone in patients with Systemic Lupus ErythematosusCTRI/2023/11/059463Dr Anirudh Maslekar
Completed
Not Applicable
Oral dexamethasone versus prednisolone in west syndromeCTRI/2021/04/032533arain Das Vaswani40
Completed
Phase 4
A comparison of oral prednisolone and oral dexamethasone in children with croup: a prospective, randomised, double blinded multicentre trialCroup (laryngotracheitis, laryngotracheobronchitis)Respiratory - Other respiratory disorders / diseasesACTRN12609000290291Dr Colin Parker1,400